Evaxion gets $24M from EIB for AI vaccine research

By The Science Advisory Board staff writers

December 9, 2020 -- The European Investment Bank (EIB) has signed a loan for 20 million euros ($24.1 million U.S.) with Evaxion Biotech to support artificial intelligence (AI) vaccine research.

Evaxion will use the loan to fund research and development for the use of artificial intelligence to determine the most suitable targets for immunotherapies for cancer and infectious diseases. The research could transform the drug discovery process for vaccines and immunotherapies, including those programs targeting Staphylococcus aureus and Pseudomonas aeruginosa.

The move is supported by the Infectious Diseases Finance Facility window under the European Union's (EU) finance for innovation program InnovFin, which provides loans for innovative projects.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.